September 26, 2017 8:00 AM ET

Life Sciences Tools and Services

Company Overview of ViroCyt, LLC

Company Overview

ViroCyt, LLC provides virus quantification solutions to the life science industry. The company focuses on replacing outdated technologies that slow down the pace of virus-related research and product development. It offers Virus Counter 3100, a tool for virus quantification that provides results for total virus particle concentration. The company sells its products directly and through distributors in North America. It also offers its products online. The company was incorporated in 2012 and is based in Boulder, Colorado. As of July 14, 2016, ViroCyt, LLC operates as a subsidiary of Sartorius AG.

2100 Central Avenue

Suite 103

Boulder, CO 80301

United States

Founded in 2012

Phone:

720-599-3700

Key Executives for ViroCyt, LLC

Chief Technology Officer
Vice President of Sales
Vice President of Marketing & Strategic Partnering
Compensation as of Fiscal Year 2017.

ViroCyt, LLC Key Developments

ViroCyt Develops Rapid Detection System for Enterovirus 71

ViroCyt Inc. announced the addition of another member of its ViroTag® portfolio of antibody-based detection reagents: ViroTag EV71. Enterovirus 71 or EV71 causes epidemics of hand, foot and mouth disease (HFMD) as well as severe neurological diseases in children, primarily in Asia. ViroCyt has created an EV71-specific detection system that-when combined with the Virus Counter 3100 instrument-enables precise quantification of the virus during a one-minute analysis.

ViroCyt® Announces a Paradigm Shift in Influenza Virus Quantification: Virotag® Invx

ViroCyt announced that it has developed and launched an antibody-based detection system for influenza capable of determining virus titer for both flu A and flu B during a one minute analysis. Every year, the flu virus causes millions of cases of illness and hundreds of thousands of deaths. The emergence of potentially pandemic strains in previous years has highlighted the need for faster methods of creating life-saving vaccines. To this end, significant investments have been made in new technologies. A primary bottleneck, however, has historically been a lack of rapid analytical systems capable of allowing in-process monitoring during the manufacturing process.

ViroCyt Releases Virotag(R) Aav2-3: Rapid and Direct Quantification of Gene Therapy Viral Vectors

ViroCyt, announced the release of the most recent addition to its ViroTag® portfolio: ViroTag AAV2-3. When combined with the Virus Counter® 3100, this reagent enables real-time quantification of Adeno-associated virus serotypes 2 and 3, both of which are currently being developed as gene therapy vectors for a variety of different diseases.

Similar Private Companies By Industry

Company Name Region
10X Genomics, Inc. United States
4G Clinical, Inc. United States
AAPharmaSyn LLC United States
Abiant, Inc. United States
aBioBot, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
\
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
The Advertising Council, Inc. United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Tax Management Inc United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact ViroCyt, LLC, please visit www.virocyt.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.